Surfactant phosphatidylcholine composition during dexamethasone treatment in chronic lung disease

AUTOR(ES)

Ashton, M R

RESUMO

Objectives - To determine whether dexamethasone `matures' the phosphatidylcholine (PC) composition of broncheoalveolar fluid in infants at high risk of neonatal chronic lung disease (CLD), either by increasing the proportion of dipalmitoylphosphatidylcholine (DPPC), expressed as a percentage of total PC (%DPPC), or by increasing the ratio of DPPC to palmitoyloleoylphosphatidylcholine (DPPC:POPC ratio).

Documentos Relacionados

• Lung surfactant in subacute pulmonary disease
• Measurement of pulmonary status and surfactant protein levels during dexamethasone treatment of neonatal respiratory distress syndrome.
• Steroids, surfactant and lung disease.
• Medical genetics: advances in brief: Partial deficiency of surfactant protein B in an infant with chronic lung disease
• Respiratory function during sleep in patients with chronic obstructive lung disease.